Maharashtra Halts Cadila Aciloc Sales Over Dangerous Brand Confusion

The Maharashtra Food and Drug Administration (FDA) has hit Cadila Pharmaceuticals Ltd. with an immediate order to stop selling and recall several 'Aciloc' branded drugs, seizing stock worth around Rs 2.45 crore across the state. This urgent action, initiated after inspections on July 9 and 10, comes over serious 'brand confusion' concerns that could lead to dangerous medication errors for patients. The problem lies with nearly identical branding for products containing different Active Pharmaceutical Ingredients (APIs): while Aciloc 150 and Aciloc 300 have Ranitidine, their 'Plus' versions – Aciloc 150 Plus and Aciloc 300 Plus – use Famotidine, a completely different drug. This isn't just about confusing names; it's a critical public health risk. FDA Commissioner Tukaram Mundhe highlighted that such deceptive similarities could easily lead doctors, pharmacists, or even patients to pick up the wrong medicine, especially since Ranitidine and Famotidine are both H2 Receptor Blockers for acid reflux but have different dosing and safety profiles. The context is crucial: Ranitidine has faced global scrutiny and bans due to N-Nitrosodimethylamine (NDMA) contamination concerns, though it's still sold in India, making the 'Aciloc Plus' branding for Famotidine particularly risky as patients might assume it's just an improved version of the Ranitidine drug. This state-level move by the Maharashtra FDA also aligns with broader national efforts, as the Central Drugs Standard Control Organisation (CDSCO) is currently seeking public input to tighten rules against similar-sounding drug brand names across India. Cadila Pharmaceuticals now faces a significant challenge, needing to recall all affected stock immediately and likely revise its branding strategy to comply with regulatory norms. The FDA has indicated that further legal action under the Drugs and Cosmetics Act, 1940, will depend on the company's response and the ongoing investigation. This incident underscores the increasing regulatory focus on patient safety in India's pharmaceutical market, pushing manufacturers nationwide to reassess their labeling and branding practices to prevent similar medication mix-ups.